In this study, we described how individuals at risk of cancer (Group 1) show a higher frequency of CRC in path_MLH1 than in path_MSH2 families (59% vs. 47%, p = 0.05018), along with a high risk of extracolonic cancer in path_MSH2 carriers (Group 2), similarly to other studies [36,37,38,39]. Here, MSH2 is linked to cancer.